The Facts

Prostate cancer is the most common male cancer and recently became the most commonly diagnosed cancer in England.


  • 300,000 men die from prostate cancer across the world, every year
  • 56,000 men diagnosed in the UK in 2018
  • 5,000 of these were under 60 years old
  • 12,000 of these are likely to die from prostate cancer
  • Only 5% of all cancer research spend goes on prostate cancer research in the UK

What's the need?

Prostate cancer is the most common male cancer and recently became the most commonly diagnosed cancer in England.


We urgently need to develop new and effective treatments for advanced prostate cancer, and to make sure that all patients have the information they need to make the right choices for them.

Globally, the funding of medical research into improved treatments has been minimal; according to the NCRI, just over £22m was spent overall on novel prostate cancer research in the UK in 2018. By way of comparison, £40–£46m has been spent on early stage breast cancer research over the last five years and mortality rates have fallen by 18% since 2014.

This is where PCR comes in. We are here to invest in the science, research and medical breakthroughs of the future, and to empower patients and their families to access the right information, have the right conversations, and get the best treatment for them.

Why us?

Our focus is on taking research from bench to bedside. In order to achieve this:


  • We help our researchers connect with patients so that they have a deeper understanding of patient’s needs and challenges
  • We help scientists build new collaborations and partnerships with other scientists
  • We monitor and evaluate our impact so that we ensure the effectiveness of our research and continue to improve our work in the future
  • Only by working in this way do we have a good chance of saving and improving lives.

 

 

What we have achieved so far

Bold science, backed by patients, that delivers


Our teams of dedicated scientists are constantly taking great strides forward to improve our understanding of why cancer behaves as it does, and how we can stop it.

Some of their key achievements so far include the discovery of a potential way to make radiotherapy work more effectively and with fewer side effects. They invented a new technique to discover networks of on/off signals for cancer, which we hope to use to develop more treatments. Our researchers also started investigating how fat fuels prostate cancer, and using AI to predict whether or not a cancer needs treatment.

We are always working to provide resources to and empower patients. We have run national campaigns to empower patients to ask questions and get the right treatment for them, and to talk about and get support for the side effects of treatment.

We do all of this in honour of the men and families who have already been through things no family should have to go through, and to create a future where no one needs to fear a prostate cancer diagnosis.

Strategy for 2020-23

Our six core strategic goals will guide all of our decision making.

Our three-year strategic plan reaffirms PCR’s overarching vision and sets out six core strategic goals that will guide all of our decisions towards helping secure a better future for men and their families affected by prostate cancer. Our strategy aims to shift perspectives and combine scientific excellence with a patient-centric approach.

Strategy 2020-2023
Gold Standard

Gold Standard


PCR aims to become the gold standard for research that has an impact on advanced prostate cancer. We are committed to being at the forefront of innovation and fostering scientific excellence and, to this end, we will actively seek out exceptional science proposed by outstanding scientists.

Leading Authority

Leading Authority


To succeed in our mission, we need to further strengthen our credibility and reputation. We aim to be recognised as the leading authority on prostate cancer research among the research community, decision-makers and funders.

Form Partnerships

Form Partnerships


Looking out for and nurturing vibrant partnerships is part of the solution to speeding up the development of pioneering treatments for cancer patients in the UK and worldwide. PCR will build bridges between the scientific community, government, pharmaceutical industry and people with prostate cancer.

Assembling Experts

Assembling Experts


We have assembled experts to advise us on all aspects of running a successful and robust research charity. We will continue to analyse and assess our skills and experience and fill gaps that may exist in our scientific advisory committee, executive advisory group and board
of trustees.

Continuous Learning

Continuous Learning


Our main objectives will be to foster a culture of continuous learning and to build a ‘shared’ sense of purpose and the autonomy to achieve goals. Capturing and preserving knowledge will also be critical to PCR’s organisational effectiveness and long-term success.

Sustainable Growth

Sustainable Growth


We will take a dual approach of bidding for larger grants from government, trusts, companies and high-net-worth individuals, while also strategically investing funds to ensure we build up the type of flexible funding that comes from events and individual giving.

Our Values

Our culture is driven by four core values which are enshrined in our work ethic and serve as the lens through which we evaluate our decisions.

Innovation

Innovation


We believe in ‘innovation’ as a mindset. We always start off our work with an open mind and are not afraid to challenge conventional views to drive innovation. We actively seek out and support good ideas from our staff and volunteers and scientists. That’s why PCR believes in investing in research that will yield long-term impact in quality of life for patients.

Collaboration

Collaboration


Through collaboration, we maximise our impact. We believe that the best results stem from bringing in a mix of perspectives, talents and experiences. Our ambition is to leverage the combined expertise of leading scientists for the greater good. Adopting a multidisciplinary approach will benefit all parties involved and ultimately advance cancer research.

Accountability

Accountability


We promote accountability and collective responsibility. We want our team to feel they can make decisions that will maximise our impact. Likewise, our drive for continuous improvement goes hand in hand with our willingness to take collective responsibility for our own actions and with our commitment to transparency. This also includes own up to our failures and correcting them wherever possible.

Empathy

Empathy


It is personal connections that bring our work to life. Our work starts and ends with people. We put patients first by listening to what matters to them. We talk in simple terms and endeavour to make science accessible to all. We believe in compassion and recognise that empathy goes a long way towards improving the quality of life of people with cancer.

Press enter or esc to cancel